Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: A possible relationship between an obstructive prosthesis and suboptimal hemodynamic recovery, as reflected by unsatisfactory regression in systolic pulmonary artery pressure (sPAP) and functional tricuspid regurgitation (FTR) following mitral valve replacement (MVR), was investigated. A delineating effective orifice area index (EOAI) value was sought in order to define a patient-prosthesis mismatch.

Methods: A total of 128 patients undergoing isolated mechanical MVR were followed up for a mean of 46 ± 9 months. Patients were allocated to two groups. Group I comprised 83 patients (65%) exhibiting a satisfactory (≥30%) regression in sPAP and FTR, while group II comprised 45 patients with a <30% (suboptimal) decrease in these parameters. A cutoff value for the prosthetic mitral valve in-vivo EAOI was explored as a predictor of postoperative hemodynamic recovery.

Results: The mean in-vivo EOAI differed significantly between the groups (1.23 cm2/m2 in group I versus 1.11 cm2/m2 in group II; p <0.0001). The consequent receiver operating characteristic curve analysis revealed an EOAI of 1.19 cm2/m2 as the cut-off value, below which a suboptimal postoperative regression in pulmonary hypertension and FTR is predicted.

Conclusions: An in-vivo EOAI <1.19 cm2/m2 strongly suggests a suboptimal hemodynamic recovery following MVR with the bileaflet mechanical prosthesis used in the present study. Although no direct relationship between prosthesis size and in vivo EOAI was demonstrated, the logical approach is to implant a prosthesis of the largest possible size.

Download full-text PDF

Source

Publication Analysis

Top Keywords

suboptimal hemodynamic
8
hemodynamic recovery
8
mitral valve
8
valve replacement
8
group comprised
8
comprised patients
8
mitral patient-prosthesis
4
patient-prosthesis mismatch
4
mismatch predicts
4
predicts suboptimal
4

Similar Publications

Hypertension constitutes a major risk factor for cardiovascular diseases. Globally, the management and control of hypertension remain suboptimal. At present, pharmacological intervention is a critical strategy for patients with hypertension to achieve blood pressure regulation.

View Article and Find Full Text PDF

Background: Evidence regarding cardiovascular adaptation to pregnancy in women with pregestational diabetes is limited. Our study aimed to describe left ventricular (LV) remodelling and vascular adaptation to pregnancy in women with type 1 diabetes.

Methods: In this prospective cohort study, three consecutive cardiac MRI scans were conducted on age-matched and BMI-matched pregnant women with pregestational type 1 diabetes and pregnant women without diabetes.

View Article and Find Full Text PDF

Background: The prognostic value of coronary artery bypass grafting (CABG) may be suboptimal when guided solely by anatomical stenosis severity. Quantitative flow ratio (QFR), a computational angiography-derived hemodynamic assessment tool, offers functional insights; however, its prognostic interplay with lesion localization [proximal vs. mid-to-distal left anterior descending artery (LAD)] remains unclear.

View Article and Find Full Text PDF

Pharmacokinetics and pharmacodynamics studies of Relugolix long-acting microcrystalline formulation in male Beagle dogs.

Eur J Pharm Sci

August 2025

Department of Pharmacy, Gansu Provincial People's Hospital. #240 Donggang West Road, Lanzhou 730000, China; School of Pharmacy, Ningxia Medical University. #116 Shengli Street, Yinchuan 750001, China. Electronic address:

Relugolix is the first oral GnRH receptor antagonist. However, its oral formulation requires daily administration, leading to poor patient adherence and suboptimal treatment outcomes for long-term users. To address these issues, we developed a long-acting microcrystalline formulation of relugolix administered once every 28 days.

View Article and Find Full Text PDF

From support to recovery: the evolving role of LVAD in reversing heart failure.

J Cardiothorac Surg

August 2025

Department of Cardiac Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences ï¿¿ Peking Union Medical College, Tianjin, 300457, China.

In recent years, the use of Left Ventricular Assist Devices (LVAD) in the treatment of heart failure has been increasingly widespread. Not only do they provide circulatory support for patients, but the reverse biological changes in myocardial tissue induced by LVAD have led to the recovery of heart function in some patients, allowing for the removal of the device-which termed bridge to recovery (BTR). Despite promising prospective studies reporting LVAD explantation rates exceeding 48-60% in BTR-focused cohorts, real-world registries (e.

View Article and Find Full Text PDF